Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]
News [3579]
Articles [92]
Editorials [5]
Conferences [157]
elearning [19]
Randomised double blind phase III safety and efficacy trial of the proposed...
Dr Hope Rugo - University of California, San Francisco, USA
Randomised double blind phase III safety and efficacy trial of the proposed trastuzumab biosimilar, MYL-1401O vs. herceptin ( Dr Hope Rugo - University of California, San Francisco, USA )
3 Jun 2016
Hodgkins - update on treatment strategies in children and adolescents
Prof Christine Mauz-Körholz - University of Giessen, Giessen, Germany
Hodgkins - update on treatment strategies in children and adolescents ( Prof Christine Mauz-Körholz - University of Giessen, Giessen, Germany )
6 May 2016
Use of novel agents in childhood ALL
Prof Lia Gore - Children's Hospital Colarado, Aurora, USA
Use of novel agents in childhood ALL ( Prof Lia Gore - Children's Hospital Colarado, Aurora, USA )
6 May 2016
Radiotherapy in Hogkin lymphoma: reducing risk in later life
Dr Graham Collins - Oxford University Hospitals NHS Foundation Trust, Oxford, UK
Radiotherapy in Hogkin lymphoma: reducing risk in later life ( Dr Graham Collins - Oxford University Hospitals NHS Foundation Trust, Oxford, UK )
6 May 2016
Relapsed Hodgkin lymphoma in PET positive patients
Dr Graham Collins - Oxford University Hospitals NHS Foundation Trust, Oxford, UK
Relapsed Hodgkin lymphoma in PET positive patients ( Dr Graham Collins - Oxford University Hospitals NHS Foundation Trust, Oxford, UK )
6 May 2016
A presurgery combination therapy may improve outcomes for women with Her2...
Dr Angela DeMichele - Perelmen School of Medicine, University of Pennsylvania...
A presurgery combination therapy may improve outcomes for women with Her2-positive breast cancer ( Dr Angela DeMichele - Perelmen School of Medicine, University of Pennsylvania, Philadelphia, USA )
6 May 2016
5 year survival rates for nivolumab-treated metastatic melanoma patients much...
Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA
5 year survival rates for nivolumab-treated metastatic melanoma patients much higher than historical rates ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )
6 May 2016
CD4 T-cell immunotherapy targeting MAGE-A3 is safe, and shows early clinical...
Dr Yong-Chen William Lu - National Cancer Institute, Bethesda, USA
CD4 T-cell immunotherapy targeting MAGE-A3 is safe, and shows early clinical responses ( Dr Yong-Chen William Lu - National Cancer Institute, Bethesda, USA )
6 May 2016
Galectins in tumour immunity
Dr Gabriel Rabinovich - Instituto de Biología y Medicina Experimental, Buenos...
Galectins in tumour immunity ( Dr Gabriel Rabinovich - Instituto de Biología y Medicina Experimental, Buenos Aires, Argentina )
5 May 2016
Treatment of relapsed myeloma with novel targeted and immune therapies
Dr Kenneth Anderson - Dana–Farber Cancer Institute, Boston, USA
Treatment of relapsed myeloma with novel targeted and immune therapies ( Dr Kenneth Anderson - Dana–Farber Cancer Institute, Boston, USA )
5 May 2016
Targeting T regs in tumours
Dr Dario Vignali - University of Pittsburgh School of Medicine, Pittsburgh, USA
Targeting T regs in tumours ( Dr Dario Vignali - University of Pittsburgh School of Medicine, Pittsburgh, USA )
5 May 2016
Direct activation of STING in the tumour microenvironment leads to potent and...
Dr Thomas Dubensky - Aduro Biotech, Berkley, USA
Direct activation of STING in the tumour microenvironment leads to potent and systemic tumour regression and immunity ( Dr Thomas Dubensky - Aduro Biotech, Berkley, USA )
4 May 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation